Chromocell Therapeutics (Chromocell Therapeutics) Additional Paid-In Capital : $17.21 Mil(As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Additional Paid-In Capital?

Chromocell Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 ($3.58 Mil) to Dec. 2023 ($7.08 Mil) and increased from Dec. 2023 ($7.08 Mil) to Mar. 2024 ($17.21 Mil).

Chromocell Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($2.43 Mil) and increased from Dec. 2022 ($2.43 Mil) to Dec. 2023 ($7.08 Mil).

Chromocell Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Chromocell Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Additional Paid-In Capital Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

2.43

7.08

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial							2.69	3.16	3.58	7.08	17.21

Chromocell Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Chromocell Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.